In Segment C, members will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Participants will acquire treatment until disease progression or the participants are unable to tolerate the study drugs. For all flow cytometry experiments, 10,000 cells per replicate have been analyzed, and 3 https://abbv-744combinationtherap57902.bloguetechno.com/details-fiction-and-clinical-effectiveness-of-abbv-744-in-aml-patients-67189166